Peer-reviewed veterinary case report
Canine nodal marginal zone lymphoma signs and outcomes
By Cozzi, M. et al.·Published in Veterinary and Comparative Oncology·2017·Department of Veterinary Medicine University of Milan Milan Italy, Italy·View original on Crossref →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Canine nodal marginal zone lymphoma: Descriptive insight into the biological behaviour
- Species:
- dog
Plain-English summary
A group of dogs diagnosed with nodal marginal zone lymphoma (nMZL) showed symptoms like swollen lymph nodes and, in some cases, general illness. All dogs were found to have advanced disease at stage V, with some also having affected organs outside the lymph nodes. They received treatment with chemotherapy or chemo-immunotherapy, but the results were not very encouraging, with a median survival time of about 259 days. This type of lymphoma is considered indolent, meaning it progresses slowly, but the overall outcome remains poor, and more research is needed to find the best treatment options.
People also search for: dog swollen lymph nodes treatment · canine lymphoma prognosis · chemotherapy for dog lymphoma
Abstract
Canine nodal marginal zone lymphoma (nMZL) is classified as an indolent lymphoma. Such lymphomas are typified by low mitotic rate and slow clinical progression. While the clinical behaviour of canine splenic MZL has been described, characterized by an indolent course and a good prognosis following splenectomy, there are no studies specifically describing nMZL. The aim of this study was to describe the clinical features of and outcome for canine nMZL. Dogs with histologically confirmed nMZL undergoing a complete staging work‐up (including blood analysis, flow cytometry [FC] on lymph node [LN], peripheral blood and bone marrow, imaging, histology and immunohistochemistry on a surgically removed peripheral LN) were retrospectively enrolled. Treatment consisted of chemotherapy or chemo‐immunotherapy. Endpoints were response rate (RR), time to progression (TTP) and lymphoma‐specific survival (LSS). A total of 35 cases were enrolled. At diagnosis, all dogs showed generalized lymphadenopathy. One‐third was systemically unwell. All dogs had stage V disease; one‐third also had extranodal involvement. The LN population was mainly composed of medium‐sized CD21+ cells with scant resident normal lymphocytes. Histology revealed diffuse LN involvement, referring to “late‐stage” MZL. Median TTP and LSS were 149 and 259 days, respectively. Increased LDH activity and substage b were significantly associated with a shorter LSS. Dogs with nMZL may show generalized lymphadenopathy and an advanced disease stage. Overall, the outcome is poor, despite the “indolent” designation. The best treatment option still needs to be defined.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on Crossref: https://doi.org/10.1111/vco.12374